好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Multiple Sclerosis Apps: The dawn of a new era: A comprehensive review
Multiple Sclerosis
P3 - Poster Session 3 (5:30 PM-6:30 PM)
15-021

Most health care providers (HCPs) are unfamiliar with the numerous applications in use or how to best utilize them to monitor disease progression or streamline office visits. The purpose of this paper is to assess the variability of these applications with regard to purpose, function, and user satisfaction.

 

Multiple sclerosis (MS) is a lifelong autoimmune disease affecting more than 2.5 million individuals globally and often causing progressive neurological symptoms. Several mobile applications have been developed for patients to track symptoms and neurologic function. 

 

A search was conducted on app stores using Apple and Android phones as well as a google search with key words: MS, multiple sclerosis and app to identify applications available for use. A medical search was conducted on pubmed and scopus to identify eligible studies that included the apps found. Information regarding apps available for perusal at international MS conferences were also surveyed. Each app was evaluated for similarities and differences.

Our inclusion criteria were English language apps that assessed neurologic function and symptom monitoring specific to MS.

Several apps were identified, including multiple sclerosis diagnosis and management, BeCare MS, Floodlight, Aby, MS Fatigue Fix, MSAA, MS Relapse Tool, MS Mosaic and MS Self. Each app contains common themes, such as assessing function status with either questions or games with different apps focusing on different end goals. All of the above apps addressed patient reported symptoms but only BeCare MS, MS Mosaic, and Floodlight assessed neurologic function.

More studies need to be conducted on the value and utility of using these applications. Physicians should be aware of what is available, as apps have the potential to incorporate data from remote monitoring to assist in treatment planning. More clinical outcome studies, assessments of ease of use and patient satisfaction studies will help identify apps that are more relevant.

 

Authors/Disclosures
Sharon Stoll, DO (Stoll Medical Group)
PRESENTER
Dr. Stoll has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for roche Genentech. Dr. Stoll has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech . Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for biogen. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for novartis. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for sanofi/genzyme. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Stoll has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS. Dr. Stoll has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics . Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono . Dr. Stoll has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Stoll has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Biogen. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi Genzyme. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for alexion. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono . Dr. Stoll has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Horizon. Dr. Stoll has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for BMS. Dr. Stoll has stock in BeCare Link LLC. Dr. Stoll has stock in Global Consult MS .
No disclosure on file
Sarah F. Wesley, MD, MPH (Columbia University College of Physicians and Surgeons) Dr. Wesley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Wesley has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Wesley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG therapeutics.
Charisse D. Litchman, MD Dr. Litchman has received personal compensation for serving as an employee of BeCare . Dr. Litchman has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Nurx. Dr. Litchman has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Allergan.